Semaglutide Tablet shortage
Semaglutide Tablet is currently listed in shortage by the FDA. The FDA lists 3 affected products. This page was last refreshed from FDA data on Sep 22, 2026.
Novo Nordisk is permanently discontinuing Rybelsus (semaglutide) tablets in the 3 mg, 7 mg, and 14 mg strengths. Novo Nordisk states these will be replaced by Ozempic (semaglutide) tablets, which are currently listed as available.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Semaglutide Tablet. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Jun 4, 2026Currently in shortage3 of 3 products affected.
-
Jun 4, 2026First reported to the FDA3 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Novo Nordisk, Inc. 📞 833-493-4689 3 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Rybelsus, Tablet, 7 mg (NDC 0169-4307-30) | — | — | Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets. | — |
| To Be Discontinued | Rybelsus, Tablet, 14 mg (NDC 0169-4314-30) | — | — | Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets. | — |
| To Be Discontinued | Rybelsus, Tablet, 3 mg (NDC 0169-4303-30) | — | — | Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets. | — |
These rows are manufacturer reports to the FDA for Semaglutide Tablet — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Semaglutide Tablet? options further down this page.
Why is Semaglutide Tablet in shortage?
Novo Nordisk has reported to the FDA that it is permanently stopping the manufacture of Rybelsus tablets in all three available strengths — the 3 mg, 7 mg, and 14 mg tablets. No specific reason for this decision was shared publicly with the FDA. According to Novo Nordisk's note, these products will be replaced by Ozempic (semaglutide) tablets.
It's worth knowing that this report reflects only what Novo Nordisk filed with the FDA about their own Rybelsus products. It does not mean semaglutide tablets are disappearing from the market entirely, as other manufacturers may have their own products listed separately.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Semaglutide Tablet, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Semaglutide Tablet?
Semaglutide tablets (Rybelsus) are currently on the FDA shortage list, and I want to walk you through what this means for you.
All three strengths are affected — the 3 mg, 7 mg, and 14 mg tablets. None of these strengths have a currently available source in this report, so there is no unaffected strength I can point you to right now.
The reason listed is that the manufacturer is discontinuing production of these tablets, and the record notes they are to be replaced by Ozempic (semaglutide) tablets. Because this is a discontinuation rather than a temporary delay, this supply problem may be permanent, and a conversation with your prescriber is the right next step.
Please do not stop, skip, or change your dose on your own — keep taking your medicine as prescribed while you sort out a plan.
- Talk with your prescriber or pharmacist soon about what to do next, since your current tablets are being discontinued.
- Ask whether an alternative form of semaglutide, such as Ozempic, is right for you — the same ingredient is still made by the manufacturer, though your pharmacy may need to check availability.
- Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
This is general, national information and may not match your local pharmacy's actual stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Semaglutide Tablet?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Semaglutide Tablet is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Ozempic | SEMAGLUTIDE 4 mg/1 | Tablet · Oral | Novo Nordisk Pharmaceutical Industries, LP | 00169-1704-30 |
| Ozempic | SEMAGLUTIDE 9 mg/1 | Tablet · Oral | Novo Nordisk Pharmaceutical Industries, LP | 00169-1709-30 |
| Ozempic | SEMAGLUTIDE 1.5 mg/1 | Tablet · Oral | Novo Nordisk Pharmaceutical Industries, LP | 00169-1715-30 |
| Rybelsus | SEMAGLUTIDE 3 mg/1 | Tablet · Oral | Novo Nordisk Pharmaceutical Industries, LP | 00169-4303-13 |
| Rybelsus | SEMAGLUTIDE 7 mg/1 | Tablet · Oral | Novo Nordisk Pharmaceutical Industries, LP | 00169-4307-13 |
| Rybelsus | SEMAGLUTIDE 14 mg/1 | Tablet · Oral | Novo Nordisk Pharmaceutical Industries, LP | 00169-4314-13 |
Alternative dosage forms of Semaglutide
A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:
Therapeutic equivalents & pricing 3 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Rybelsus 14 mg | Novo | 30 tablets | $33.162 | — | Availability likely |
| Rybelsus 3 mg | Novo | 30 tablets | $33.163 | — | Availability likely |
| Rybelsus 7 mg | Novo | 30 tablets | $33.195 | — | Availability likely |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Semaglutide Tablet — that fall in the same broad treatment class (antihypergly,incretin mimetic(glp-1 recep.agonist)) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other endocrinology/metabolism shortages
Semaglutide Tablet shortage FAQs
Is Semaglutide Tablet in shortage?
Which products are affected?
When will Semaglutide Tablet be available again?
Can I still get Semaglutide somewhere?
What should I do if I take Semaglutide Tablet?
Still have a question about the Semaglutide Tablet shortage?
Ask a pharmacist about this shortage →View Semaglutide Tablet on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.